New approach to treating castration-resistant prostate cancer
Official title: A novel targetable mechanism for castration-resistant prostate cancer
Funded at Veterans Health Administration · NIH-11402383 · Data updated 2026-11-12
A researcher is exploring a new mechanism that could be targeted to treat castration-resistant prostate cancer (CRPC), especially in veterans, by understanding how certain signaling pathways drive resistance to current therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Veterans Health Administration NIH-funded |
| Lab location | 1 site (Long Beach, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2027 |
| NIH project number | 5I01BX005105-05 |
| Project ID | NIH-11402383 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are men with castration-resistant prostate cancer, particularly veterans, who may benefit from future targeted therapies arising from this work.
✕Less likely to help
Patients without CRPC or those who would not have access to future targeted therapies may not benefit.
What this research studies
This project looks at how CRPC develops resistance to androgen deprivation and newer drugs. It focuses on the Slit/Robo signaling pathway and its interaction with Wnt/β-catenin signaling, which may drive tumor survival. The team has preliminary data showing srGAP1 and other components are altered in CRPC and may link to AR signaling and AR variants. The goal is to identify a targetable mechanism that could lead to new treatments for CRPC.
Why it matters
Potential benefit: If successful, the research could lead to new therapy targets that help men with CRPC respond better to treatment.
How similar studies have gone: Preliminary data suggest a plausible link between Slit/Robo signaling and CRPC, indicating potential for translation to therapy but remains early-stage.
Where this research is happening
-
Veterans Health Administration
Long Beach, United States Active
Researchers
- Principal investigator: Zi, Xiaolin — Veterans Health Administration
- Study coordinator: Zi, Xiaolin
Related research
Other NIH-funded projects on the same topics.
-
Understanding how aggressive cell states emerge in castration-resistant prostate cancer
A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.
-
Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer
Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.
-
Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer
Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.
-
Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy
This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer
A cancer research effort aimed at understanding and tackling how aggressive prostate cancers become resistant to standard AR-targeted therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.